Switch theme
Sign up to access all valuation multiples
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
1984
34
LTM Revenue $0.9M
LTM EBITDA -$257M
$490M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Opthea has a last 12-month revenue of $0.9M and a last 12-month EBITDA of -$257M.
In the most recent fiscal year, Opthea achieved revenue of $0.1M and an EBITDA of -$125M.
Opthea expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Opthea valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.1M | $0.1M | XXX | XXX | XXX |
| Gross Profit | -$26K | -$37K | XXX | XXX | XXX |
| Gross Margin | -38% | -47% | XXX | XXX | XXX |
| EBITDA | -$84.8M | -$125M | XXX | XXX | XXX |
| EBITDA Margin | -124425% | -159858% | XXX | XXX | XXX |
| Net Profit | -$58.3M | -$89.6M | XXX | XXX | XXX |
| Net Margin | -85620% | -114322% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Opthea's stock price is AUD 1 (or $0).
Opthea has current market cap of AUD 739M (or $464M), and EV of AUD 779M (or $490M).
See Opthea trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $490M | $464M | XXX | XXX | XXX | XXX | $-0.18 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Opthea has market cap of $464M and EV of $490M.
Opthea's trades at 884.5x LTM EV/Revenue multiple, and -3.0x LTM EBITDA.
Analysts estimate Opthea's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Opthea and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $490M | XXX | XXX | XXX |
| EV/Revenue | 1372.0x | XXX | XXX | XXX |
| EV/EBITDA | -3.5x | XXX | XXX | XXX |
| P/E | -2.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -4.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpOpthea's NTM/LTM revenue growth is 154%
Opthea's revenue per employee for the last fiscal year averaged $2K, while opex per employee averaged $3.5M for the same period.
Over next 12 months, Opthea's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Opthea's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Opthea and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -39546% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 48% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -39392% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $2K | XXX | XXX | XXX | XXX |
| Opex per Employee | $3.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 12424% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 141439% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 153985% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Opthea acquired XXX companies to date.
Last acquisition by Opthea was XXXXXXXX, XXXXX XXXXX XXXXXX . Opthea acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Opthea founded? | Opthea was founded in 1984. |
| Where is Opthea headquartered? | Opthea is headquartered in Australia. |
| How many employees does Opthea have? | As of today, Opthea has 34 employees. |
| Who is the CEO of Opthea? | Opthea's CEO is Dr. Frederic Guerard, Pharm.D.. |
| Is Opthea publicy listed? | Yes, Opthea is a public company listed on ASX. |
| What is the stock symbol of Opthea? | Opthea trades under OPT ticker. |
| When did Opthea go public? | Opthea went public in 1991. |
| Who are competitors of Opthea? | Similar companies to Opthea include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Opthea? | Opthea's current market cap is $464M |
| What is the current revenue of Opthea? | Opthea's last 12-month revenue is $0.9M. |
| What is the current EBITDA of Opthea? | Opthea's last 12-month EBITDA is -$257M. |
| What is the current EV/Revenue multiple of Opthea? | Current revenue multiple of Opthea is 884.5x. |
| What is the current EV/EBITDA multiple of Opthea? | Current EBITDA multiple of Opthea is -3.0x. |
| What is the current revenue growth of Opthea? | Opthea revenue growth between 2023 and 2024 was 15%. |
| Is Opthea profitable? | Yes, Opthea is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
